FDA approves Alzheimer’s drug donanemab after months of delay
The Food and Drug Administration granted approval Tuesday to a closely watched Alzheimer’s drug, concluding that the benefits of modestly slowing the progression of the devastating disease outweigh its risks, drugmaker Eli Lilly announced. The agency... [5067 chars]
Source: The Washington Post
